Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-7

  Borgers, Anke J ^a   Alkemade, Anneke ^a   van de Giessen, Elsmarieke M ^a   Drent, Madeleine L ^b   Booij, Jan ^a   Bisschop, Peter H ^a   Fliers, Eric ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Human; Hypothalamus; Pituitary insufficiency; Serotonin transporter imaging; SERT; SPECT

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA(4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN DEFICIENCY; DRUG ACTIVITY; DRUG PROTEIN BINDING; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPITUITARISM; HYPOTHALAMUS; HYPOTHALAMUS DISEASE; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84878803944     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-34     Document Type: Article

References (55)

1. Swaab DF: Human Hypothalamus: Basic and Clinical Aspects, Part II. Amsterdam: Elsevier; 2004.
2. Amir S, Robinson B, Ratovitski T, Rea MA, Stewart J, Simantov R: A role for serotonin in the circadian system revealed by the distribution of serotonin transporter and light-induced Fos immunoreactivity in the suprachiasmatic nucleus and intergeniculate leaflet. Neuroscience 1998, 84:1059-1073.
3. Curzon G: Serotonin and appetite. Ann N Y Acad Sci 1990, 600:521-530.
4. Horiuchi J, McDowall LM, Dampney RA: Differential control of cardiac and sympathetic vasomotor activity from the dorsomedial hypothalamus. Clin Exp Pharmacol Physiol 2006, 33:1265-1268.
5. Jorgensen HS: Studies on the neuroendocrine role of serotonin. Dan Med Bull 2007, 54:266-288.
6. Oberndorfer S, Saletu-Zyhlarz G, Saletu B: Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 2000, 42:69-81.
7. Ljubic-Thibal V, Morin A, Diksic M, Hamel E: Origin of the serotonergic innervation to the rat dorsolateral hypothalamus: retrograde transport of cholera toxin and upregulation of tryptophan hydroxylase mRNA expression following selective nerve terminals lesion. Synapse 1999, 32:177-186.
8. Petrov T, Krukoff TL, Jhamandas JH: Chemically defined collateral projections from the pons to the central nucleus of the amygdala and hypothalamic paraventricular nucleus in the rat. Cell Tissue Res 1994, 277:289-295.
9. Leibowitz SF, Alexander JT: Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998, 44:851-864.
10. Sakaguchi T, Arase K, Fisler JS, Bray GA: Effect of a high-fat diet on firing rate of sympathetic nerves innervating brown adipose tissue in anesthetized rats. Physiol Behav 1989, 45:1177-1182.
11. Rosenwasser AM: Functional neuroanatomy of sleep and circadian rhythms. Brain Res Rev 2009, 61:281-306.
12. Borgers AJ, Romeijn N, Van SE, Fliers E, Alkemade A, Bisschop PH: Compression of the optic chiasm is associated with permanent shorter sleep duration in patients with pituitary insufficiency. Clin Endocrinol (Oxf) 2011, 75:347-353.
13. Bray GA, Gallagher TF Jr: Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine (Baltimore) 1975, 54:301-330.
14. Martin JB, Riskind PN: Neurologic manifestations of hypothalamic disease. Prog Brain Res 1992, 93:31-40.
15. Stahl: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. New York: Cambridge University Press; 2000.
16. Koch W, Schaaff N, Popperl G, Mulert C, Juckel G, Reicherzer M, Ehmer-von GC, Moller HJ, Hegerl U, Tatsch K, Pogarell O: [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J Psychiatry Neurosci 2007, 32:234-240.
17. Willeit M, Stastny J, Pirker W, Praschak-Rieder N, Neumeister A, Asenbaum S, Tauscher J, Fuchs K, Sieghart W, Hornik K, Aschauer HN, Brücke T, Kasper S: No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 2001, 50:8-12.
18. 123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 2007, 32:1661-1668.
19. Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, Zettinig G, Hornik K, Pirker W, Thau K: Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2008, 33:3126-3134.
20. Peterson TE, Shokouhi S: Advances in preclinical SPECT instrumentation. J Nucl Med 2012, 53:841-844.
21. 11C]DASB PET study. NeuroImage 2011, 54:1336-1343.
22. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007, 48:359-366.
23. 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med 2012, 53:1087-1090.
24. Booij J, Knol RJ, Reneman L, De BK, Janssen AG, Van Royen EA: Iodine-123 labelled nor-beta-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. Eur J Nucl Med 1998, 25:1666-1669.
25. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997, 27:183-190.
26. 123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000, 27:346-349.
27. 123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 2002, 46:199-205.
28. 125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 1994, 62:549-556.
29. Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, Edenbrandt L, Flotats A, Germano G, Stopar TG, Franken P, Kelion A, Kjaer A, Le Guludec D, Ljungberg M, Maenhout AF, Marcassa C, Marving J, McKiddie F, Schaefer WM, Stegger L, Underwood R: EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging 2008, 35:851-885.
30. Manley PE, McKendrick K, McGillicudy M, Chi SN, Kieran MW, Cohen LE, Kothare S, Michael SR, Goumnerova LC, Sun P, London W, Marcus KJ, Pomeroy SL, Ullrich NJ: Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol 2012, 108:543-549.
31. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998, 25:24-30.
32. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:133-140.
33. van Herk M, de Jaeger K, de Munck J, Hoogeman M, Meinders J, Ploeger L: A delineation system for N modalities-software aspects [extended abstract]. In 13th ICCR: May 22-25 2000. Heidelberg. New York: Springer; 2000:73.
34. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE: Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27:1533-1539.
35. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994, 14:982-994.
36. Dahlstrom M, Ahonen A, Ebeling H, Torniainen P, Heikkila J, Moilanen I: Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry 2000, 5:514-522.
37. Anderson E, Haymaker W: Breakthroughs in hypothalamic and pituitary research. Prog Brain Res 1974, 41:1-60.
38. Braak H, Braak E: Anatomy of the human hypothalamus (chiasmatic and tuberal region). Prog Brain Res 1992, 93:3-14.
39. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, Baldwin RM, Innis RB: Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging 2000, 21:497-501.
40. Chou YH, Yang BH, Chung MY, Chen SP, Su TP, Chen CC, Wang SJ: Imaging the serotonin transporter using (123)I-ADAM in the human brain. Psychiatry Res 2009, 172:38-43.
41. 123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men. Eur J Nucl Med Mol Imaging 2010, 37:1507-1511.
42. 11C McN 5652. Psychopharmacology (Berl) 2002, 164:341-348.
43. 11C]DASB and positron emission tomography. Biol Psychiatry 2006, 59:821-828.
44. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, Houle S, Meyer JH: Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005, 32:123-128.
45. Emiliano AB, Cruz T, Pannoni V, Fudge JL: The interface of oxytocinlabeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRIs therapeutic effects? Neuropsychopharmacology 2007, 32:977-988.
46. Legutko R, Gannon RL: Serotonin transporter localization in the hamster suprachiasmatic nucleus. Brain Res 2001, 893:77-83.
47. Moore RY, Speh JC: Serotonin innervation of the primate suprachiasmatic nucleus. Brain Res 2004, 1010:169-173.
48. Biermasz NR, Joustra SD, Donga E, Pereira AM, Van DN, Van DM, Van der Klaauw AA, Corssmit EP, Lammers GJ, van Kralingen KW, van Dijk JG, Romijn JA: Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 2011, 96:1524-1532.
49. Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JW, Romijn JA: Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006, 91:3364-3369.
50. Kendall-Taylor P, Jonsson PJ, Abs R, Erfurth EM, Koltowska-Haggstrom M, Price DA, Verhelst J: The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol 2005, 152:557-567.
51. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA: Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993, 129:195-200.
52. Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR: Coping strategies in patients after treatment for functioning or nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2011, 96:964-971.
53. van der Klaauw AA, Dekkers OM, Pereira AM, van Kralingen KW, Romijn JA: Increased daytime somnolence despite normal sleep patterns in patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007, 92:3898-3903.
54. Van Someren EJ, Swart-Heikens J, Endert E, Bisschop PH, Swaab DF, Bakker PJ, Romijn JA, Fliers E: Long-term effects of cranial irradiation for childhood malignancy on sleep in adulthood. Eur J Endocrinol 2004, 150:503-510.
55. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV: Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001, 55:735-740.